Tempus AI’s (TEM) Buy Rating Reiterated at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating reissued by equities research analysts at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $80.00 price objective on the stock. BTIG Research‘s price target would suggest a potential upside of 19.58% from the stock’s previous close.

Several other research firms have also issued reports on TEM. Guggenheim lifted their price target on Tempus AI from $65.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Roth Capital initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. Stifel Nicolaus decreased their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Rothschild & Co Redburn initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 target price for the company. Finally, UBS Group initiated coverage on Tempus AI in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 target price for the company. Eleven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $72.47.

Tempus AI Price Performance

TEM traded down $0.71 on Monday, reaching $66.90. The company had a trading volume of 1,776,944 shares, compared to its average volume of 6,169,105. The company has a market cap of $12.07 billion, a price-to-earnings ratio of -46.26 and a beta of 3.54. Tempus AI has a 52-week low of $40.77 and a 52-week high of $93.38. The business has a 50 day simple moving average of $69.24 and a 200 day simple moving average of $57.26. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s revenue was up 21.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) earnings per share. As a group, sell-side analysts anticipate that Tempus AI will post -1.43 EPS for the current year.

Insider Buying and Selling

In related news, EVP Andrew Polovin sold 2,951 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $75.00, for a total value of $221,325.00. Following the completion of the sale, the executive vice president directly owned 135,189 shares of the company’s stock, valued at approximately $10,139,175. This represents a 2.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 700 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $70.00, for a total transaction of $49,000.00. Following the completion of the sale, the chief executive officer directly owned 15,874 shares of the company’s stock, valued at $1,111,180. This represents a 4.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,280,965 shares of company stock worth $80,397,564 in the last ninety days. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Group Inc. boosted its stake in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock worth $195,636,000 after purchasing an additional 821,490 shares during the period. Amova Asset Management Americas Inc. boosted its position in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after acquiring an additional 821,490 shares during the last quarter. Eagle Health Investments LP bought a new position in shares of Tempus AI during the 1st quarter valued at approximately $11,588,000. Washington Trust Advisors Inc. boosted its position in shares of Tempus AI by 35.7% during the 3rd quarter. Washington Trust Advisors Inc. now owns 121,039 shares of the company’s stock valued at $9,913,000 after acquiring an additional 31,873 shares during the last quarter. Finally, Swiss National Bank boosted its position in shares of Tempus AI by 0.3% during the 1st quarter. Swiss National Bank now owns 183,500 shares of the company’s stock valued at $8,298,000 after acquiring an additional 600 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.